Erasca, Inc.
NASDAQ:ERAS · NASDAQ Global Select
-$0.02 today
Vol 7.97M · Avg 6.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.3%
avg -29.7%
ROIC
-35.3%
avg -44.6%
ROA
-31.4%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -31.4% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | $1.16M | — | 54 | $2.00M | 0.64% |
David Chacko | Chief Financial Officer & Chief Business Officer | $775,216.00 | — | 42 | $640,000.00 | 0.21% |
Shannon Morris | Chief Medical Officer | $772,700.00 | — | 56 | $0.00 | <0.01% |
Ebun S. Garner | Chief Legal Officer & Corporate Secretary | $607,440.00 | — | 54 | $25,076.00 | <0.01% |
Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | $93,181.00 | — | 68 | $96,000.00 | 0.03% |
Lisa Tesvich-Bonora | Chief People Officer | — | — | — | — | — |
Robert Shoemaker | Chief Scientific Officer | — | — | 45 | — | — |
Dawei Xuan | Senior Vice President of Clinical Pharmacology | — | — | — | — | — |
Alison Tjosvold Milhous | Senior Vice President of Accounting | — | — | 47 | — | — |
Chandra D. Lovejoy | Chief Regulatory Affairs Officer | — | — | 55 | — | — |
Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | — | — | — | — | — |
Brian L. Baker | Senior Vice President of Finance | — | — | 59 | — | — |
Nik Chetwyn | Chief Operating Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$2.28M
Net Sentiment
$2.28M
Net selling
Most Active
Garner Ebun
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Garner Ebun Direct | Sell | 80.0K | $16.40 | $1,312,000.00 | |
| Mar 4, 2026 | Morris Shannon Direct | Sell | 20.0K | $15.04 | $300,760.00 | |
| Jan 7, 2026 | Garner Ebun Direct | Sell | 120.0K | $5.59 | $670,812.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $2.28M over the last 12 months. That adds up to net selling of $2.28M. Garner Ebun was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.49B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.43B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.41B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.41B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.02B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.01B
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$509.01M
Arvinas, Inc.
NASDAQ:ARVN
$496.81M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.82M
Who manages ERAS?
Erasca, Inc. (ERAS) lists 13 active executives. The top listed executive is Jonathan E. Lim, Co-Founder, Chairman & Chief Executive Officer.
Are ERAS insiders buying or selling?
Recent insider activity shows net buying of $102.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.